Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 55Neoplasms 15Sarcoma 12Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Ovarian Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Liposarcoma 2Leiomyosarcoma 2Carcinoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Lymphoma 1

Interventions

eribulin 1Irinotecan 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Relapsed Solid Tumors × eribulin × Clear all
NCT02596503 2022-02-15

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

University of Colorado, Denver

Phase 1 Completed
2 enrolled
Other solid neoplasm

Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡